The aim of this study was to investigate whether the nitric oxide (NO) pathway is altered in pregnancies that develop preeclampsia (PE). This was a nested case --control study of screening for PE, in which plasma asymmetric dimethylarginine (ADMA), L-arginine and L-homoarginine were measured at 11 þ 0 --13 þ 6 weeks. In all, 75 pregnancies that developed PE, including 25 requiring delivery before 34 weeks (early PE), and 300 unaffected controls were included. L-arginine and L-homoarginine were measured by gas chromatography-mass spectrometry, whereas ADMA was measured by gas chromatography-tandem mass spectrometry. Multiple regression analysis was used to determine if any maternal characteristics or gestation were significant predictors. In the early-PE group, both L-arginine and L-homoarginine expected medians (MoMs) were significantly reduced (median, IQR: 0.85, 0.76 --1.04 vs 0.98, 0.88 --1.16, P ¼ 0.021 and 0.78, 0.65 --0.96 vs 0.99, 0.77 --1.31, P ¼ 0.006, respectively) but ADMA MoMs were not significantly different (P ¼ 0.599). In early PE, compared with controls, the ratios of ADMA to L-arginine MoMs and ADMA to L-homoarginine MoMs were increased (median, IQR: 1.19, 0.94 --1.33 vs 1.01, 0.75 --1.31, P ¼ 0.003 and 1.21, 0.93 --1.61 vs 0.99, 0.87 --1.16, P ¼ 0.012, respectively). There were no significant differences between late PE and controls in ADMA, L-arginine, L-homoarginine or their ratios. In conclusion, development of early PE is associated with altered NO metabolism and/or synthesis apparent from the first trimester.
INTRODUCTION
Normal pregnancy is associated with widespread vasodilatation, which is thought to be mediated by nitric oxide (NO). 1 NO is present in syncytiotrophoblast and in the fetoplacental vascular endothelium where it contributes to low fetoplacental vascular resistance. It is also an important regulator of trophoblast functions, such as implantation, differentiation, motility, invasion and apoptosis.
2 --5 L-arginine is the substrate for the enzyme NO synthase (NOS) and asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of this enzyme. 6, 7 L-homoarginine can replace L-arginine as a substrate for the biosynthesis of NO. 8, 9 Studies have demonstrated a significant association between elevated ADMA levels and cardiovascular disease. 10, 11 Infusion of ADMA is associated with endothelial dysfunction. 12 The ratio of L-arginine to ADMA is associated with altered NOS activity 13 and is a useful index for evaluating the effects of ADMA. 7, 14 NO, along with its substrates and inhibitors, is thought to have an important role in the pathophysiology of preeclampsia (PE), which is characterized by widespread vasoconstriction. Several studies have reported that in PE the maternal plasma concentration of ADMA is increased, whereas the concentration of L-arginine is decreased, increased or normal. 15 --24 There is some evidence that altered maternal concentration of these metabolites may precede the clinical onset of the disease. 21, 25 L-homoarginine levels are increased in normal pregnancy, but we were unable to locate any studies examining its levels in pathological pregnancies. 26 The aim of this study was to investigate further the possible role of NO in the pathogenesis of PE by comparing maternal plasma levels of ADMA, L-arginine and L-homoarginine at 11 --13 weeks' gestation in women who subsequently developed PE with unaffected controls.
MATERIALS AND METHODS

Study population
This was an observational case --control study (between March 2006 and June 2009) drawn from a large prospective screening study on early prediction of complications of pregnancy in women attending for their routine first hospital visit at King's College Hospital, London, UK. At this visit, which is held at 11 þ 0 --13 þ 6 weeks of gestation, we perform combined screening for aneuploidies from the ultrasound measurements of fetal crown-rump length and nuchal translucency thickness, and the maternal serum concentrations of pregnancy associated plasma protein-A and free b-human chorionic gonadotropin (b-hCG) (Delfia Xpress Analyzer, Perkin Elmer Life and Analytical Sciences, Waltham, MA, USA). 27, 28 In addition, we record maternal characteristics and medical history, measure the maternal weight and height, and store maternal serum and plasma samples collected in EDTA tubes at 80 1C for subsequent biochemical analysis. Written informed consent is obtained from all women agreeing to participate in the study, which was approved by King's College Hospital Ethics Committee.
Maternal plasma ADMA, L-arginine and L-homoarginine were measured in singleton pregnancies delivering phenotypically normal neonates, 25 cases that later developed PE and required delivery before 34 weeks (early PE), 50 cases of PE delivering at or after 34 weeks (late PE) and 300 unaffected controls. Each case of PE was matched with four controls, which had blood collected on the same day and subsequently delivered a neonate with appropriate weight for gestational age at term and did not develop any hypertensive disorder of pregnancy. None of the samples were previously thawed and refrozen.
Outcome measures
Data on pregnancy outcomes were obtained from the computerized maternity unit records. The definition of PE was that of the International Society for the Study of Hypertension in Pregnancy. 29 The systolic blood pressure should be X140 mm Hg and/or the diastolic blood pressure should be X90 mm Hg, developing after 20 weeks of gestation, together with significant proteinuria in a previously normotensive woman. Significant proteinuria is defined by X300 mg in 24 h or two readings of at least þ þ on dipstick analysis of midstream or catheter urine specimens if no 24-hour collection is available. In PE superimposed on chronic hypertension, significant proteinuria (as defined above) should develop after 20 weeks of gestation in women with known chronic hypertension (history of hypertension before conception or the presence of hypertension at the booking visit before 20 weeks of gestation in the absence of trophoblastic disease).
Sample analysis
The researchers performing the assays were not aware of the clinical data of the patients. Maternal plasma L-arginine and L-homoarginine were measured by gas chromatography-mass spectrometry (GC-MS) as described previously for L-arginine with minor modifications. 30 Plasma ADMA was measured by gas chromatography-tandem mass spectrometry (GC-MS/MS) as described elsewhere. 31 For all analytes trideuteromethyl ester derivatives were produced from unlabeled synthetic standards (from Sigma, Deisenhofen, Germany) and tetradeutero-methanol (from Aldrich, Steinheim, Germany) in situ and used as internal standards. 32 The concentrations of the internal standards were 50 mmol l À1 for L-arginine, 5 mmol l À1 for L-homoarginine and 1 mmol l À1 for ADMA. Ultrafiltrates from 0.5-ml aliquots of plasma samples were obtained by centrifugation (8000 g, 20 1C, 20 min) using Vivaspin 2 Hydrosart cartridges (Sartorius; Gö ttingen, Germany) with a cutoff of 10 kDa. Aliquots (10 ml) of plasma ultrafiltrate were used for quantification of all analytes. Endogenous and stable-isotope labeled ADMA, L-arginine and L-homoarginine were converted to their methyl ester pentafluoropropionyl derivatives. GC-MS analyses were performed on a Thermo Fisher DSQ instrument (Dreieich, Germany). GC-MS/MS analyses were performed on a ThermoQuest TSQ 7000 instrument (Finnigan MAT, San Jose, CA, USA). GC-MS and GC-MS/MS conditions were essentially the same as previously described. 31, 32 The gas chromatographs were each equipped with a fused-silica capillary column Optima 17 MS (30 m, 0.25 mm ID, 0.25 mm film thickness) (Macherey-Nagel, Dü ren, Germany). Aliquots (1 ml) from toluene extracts were injected in the splitless mode in both instruments. Quantification was performed by selected ion monitoring of m/z 586 and m/z 600 for endogenous L-arginine and L-homoarginine, and of m/z 589 and m/z 603 for their internal standards. Quantification of ADMA was performed by selected reaction monitoring of the transitions m/z 634 -m/z 378 for endogenous ADMA and m/z 637 -m/z 378 for the internal standard. The dwell time was 50 ms for each ion in GC-MS and GC-MS/MS.
Study samples were analyzed within four runs alongside 16 quality control samples including human plasma samples both unspiked and spiked with 50 mmol l À1 of L-arginine, 2 mmol l À1 of L-homoarginine and 0.5 mmol l À1 of ADMA. Quality control samples were analyzed in duplicate in each run. Basal plasma concentrations were 0.39±0.02 mmol l À1 ADMA, 57.6 ± 2.1 mmol l À1 L-arginine and 1.72 ± 0.06 mmol l À1 L-homoarginine. For ADMA, inter-assay imprecision (relative s.d.) was 6.3% for unspiked and 3.7% for spiked samples; mean inter-assay accuracy (recovery) for spiked samples was 98%. For L-arginine and L-homoarginine, inter-assay imprecision was 3.6% and 3.7%, respectively, for unspiked, and 3.4% and 3.4%, respectively, for spiked samples. Mean inter-assay accuracy (recovery) for spiked samples was 92.8% for L-arginine and 90.3% for L-homoarginine.
Statistical analysis
Maternal and fetal characteristics were compared using w 2 -square test or Fisher's exact test for categorical variables and Mann --Whitney U-test with post hoc Bonferroni correction for continuous variables. The distributions of maternal plasma levels of L-arginine and L-homoarginine were logarithmically transformed and Gaussian normality was examined using histograms and probability plots. ADMA levels were normally distributed. Multiple regression analysis was used in the unaffected group to determine if any maternal characteristics or gestation were significant predictors of ADMA, log 10 L-arginine and log 10 L-homoarginine. These algorithms were then used to convert the measured levels in all cases and controls into multiples of the expected median (MoM) in the unaffected group. Nonparametric analysis using Mann --Whitney U-test with post hoc Bonferroni correction was then used to compare the median MoMs of ADMA, L-arginine and L-homoarginine between the outcome groups.
The statistical software package SPSS 17.0 (SPSS Inc., Chicago, IL, USA) was used for data analysis.
Literature search A search of PubMed and EMBASE was made to identify previous citations in the English literature examining maternal circulating concentrations of ADMA, L-arginine and L-homoarginine and PE. We used medical subject heading terms and key words related to PE, including 'arginine', 'homoarginine', 'ADMA', 'asymmetric dimethyl arginine', 'PE', 'pregnancy hypertension', 'pregnancy-induced hypertension' and 'hypertension and pregnancy'.
RESULTS
The maternal and pregnancy characteristics of the early-PE, late PE and unaffected controls are compared in Table 1 . In the PE groups there was a higher body mass index, and more women were of African and South Asian racial origin, had chronic hypertension, developed PE in their previous pregnancy and their mother had PE.
Unaffected group Multiple regression analysis in the unaffected group demonstrated that for plasma ADMA a significant independent contribution was provided by maternal weight and African racial origin but not by maternal age (P ¼ 0.690), fetal crown-rump length (P ¼ 0.266), smoking status (P ¼ 0.298), parity (P ¼ 0.890) or mode of conception (P ¼ 0.408). In the case of plasma L-arginine, a significant independent contribution was provided by maternal age but not by racial origin (P ¼ 0.569), fetal crown-rump length (P ¼ 0.395), maternal weight (P ¼ 0.519), smoking status (P ¼ 0.207), parity (P ¼ 0.246) or mode of conception (P ¼ 0.711). The level of plasma L-homoarginine was significantly affected by maternal age, maternal weight and parity but not by racial origin (P ¼ 0.080), fetal crown-rump length (P ¼ 0.948), smoking status (P ¼ 0.206) or mode of conception (P ¼ 0.980) ( Table 2) .
PE group
In the pregnancies that subsequently developed early PE, compared with the unaffected group, the median plasma levels of both L-arginine MoM and L-homoarginine MoM were significantly lower (P ¼ 0.021 and 0.006, respectively), the ratios of ADMA to L-arginine and ADMA to L-homoarginine were higher (P ¼ 0.003 and 0.012, respectively) but the median ADMA MoM was not significantly different (P ¼ 0.599) ( Table 3 ). In late PE compared with unaffected controls, there was no significant difference in the levels of ADMA MoM (
The findings were similar in the pregnancies developing earlyand late PE after exclusion of the women who had chronic hypertension. In the early-PE group, compared with the unaffected group, the median plasma levels of both L-arginine MoM and L-homoarginine MoM were significantly lower (P ¼ 0.028 and 0.011, respectively), the ratios of ADMA to L-arginine and ADMA to L-homoarginine were higher (P ¼ 0.01 and 0.034, respectively) but the median ADMA MoM was not significantly different (P ¼ 0.670). In late-PE group, compared with unaffected controls, there was no significant difference in the levels of ADMA MoM (
Literature search The results of the literature search on maternal circulating concentrations of ADMA and L-arginine in pregnancies with PE are summarized in Table 4 . Most studies reported that in pregnancies with PE the level of ADMA is increased, whereas L-arginine was decreased, increased or not significantly different from controls.
DISCUSSION
The findings of this study demonstrate that in pregnancies, which subsequently develop early --PE, the maternal plasma concentration of L-arginine and L-homoarginine at 11 --13 weeks' gestation is decreased, whereas the concentration of ADMA is not significantly altered. In women who develop late PE there are no significant differences from normotensive controls in plasma L-arginine, Lhomoarginine or ADMA.
The strengths of our study are firstly, distinction between earlyand late PE, second, adjustment of measured concentrations of plasma ADMA, L-arginine and L-homoarginine for the maternal factors that affect these measurements and third, examination of a large number of cases. The main weakness resides in the design of the study, which was case --control rather than prospective.
Our findings suggest that development of early PE, but not late PE, is associated with altered NO metabolism and/or synthesis, which is apparent from the first trimester of pregnancy. Reduced concentrations of L-arginine and L-homoarginine, which are the substrates for NOS, could result in impaired synthesis of NO. These data provide further support for the emerging evidence that PE does not constitute a homogeneous entity. Early PE is associated with impaired trophoblastic invasion of the maternal spiral arteries, reduced placental perfusion and fetal growth restriction. 32 --34 In contrast, in late PE placental perfusion and fetal growth are often normal and the main pathophysiological processes resemble those of the metabolic syndrome with an increase in adipose tissue and impaired glucose and lipid metabolism. 34 --39 In early PE the associated impaired placentation is reflected in decreased maternal circulating levels of the angiogenic factor placental growth factor and increased levels of the antiangiogenic soluble endoglin from the first trimester of pregnancy. 40, 41 There is an inverse relationship between antiangiogenic factors and circulating nitrite levels. 42 Endoglin modulates endothelial NOS expression and activity which leads to the endothelial dysfunction seen in PE. 43 --46 Previous studies examining maternal circulating levels of L-arginine before and during PE reported contradictory results. Similarly, there is contradictory evidence concerning the value of L-arginine supplementation in reducing the incidence and/or severity of PE. 47 --50 Discrepancies between the studies in the reported levels of L-arginine in PE may reflect differences in populations examined and study designs, but also the different techniques for analysis of samples, including enzyme-linked immunosorbent assay, high-performance liquid chromatography and liquid chromatography-mass spectrometry. In our study we used GC-MS/MS, which is currently one of the most reliable techniques. 51 A previous study by our group reported elevated ADMA plasma levels, impaired uterine perfusion and flow-mediated vasodilation in the brachial artery in the second trimester in women who later developed PE. 25 The difference in the ADMA levels between our two studies could be explained by the differences in technique and gestational age at sampling.
Racial origin
We could not identify any previous reports examining the association between PE and circulating levels of L-homoarginine. One previous study in normal pregnancies reported that serum Lhomoarginine concentrations in the first trimester are similar to those in nonpregnant women, but there is a subsequent increase with gestation. 26 This increase may be mediated by estrogen, which has been shown to stimulate the expression of the Larginine: glycine amidinotransferase gene. 52 The serum concentration of L-homoarginine was positively correlated with baseline brachial artery diameter and flow-mediated dilation, suggesting that this amino acid may have a role in endothelial function. 26 Such a role of L-homoarginine in endothelial function is supported by the findings of a study in patients undergoing coronary angiography or maintenance hemodialysis, where a low serum level of L-homoarginine was a strong predictor of subsequent mortality. 53 Homoarginine may also inhibit platelet aggregation and stimulate insulin secretion, 54 --56 actions, which affect cardiovascular health and may have a role in PE.
Most previous studies reported that PE is associated with increased maternal levels of ADMA. Our findings indicate that this increase is not apparent from the first trimester of pregnancy. It was previously suggested that the key determinant of NOS activity is provided by the balance between ADMA and L-arginine, as reflected in the L-arginine to ADMA ratio, 13 rather than the concentration of the individual markers. 7, 14 We found that at 11 --13 weeks in pregnancies that subsequently develop early PE both the ratios of L-arginine to ADMA and L-homoarginine to ADMA are reduced with consequent likely decrease in NOS activity.
Our results provide evidence that the development of early PE is associated with altered NO metabolism and/or synthesis, which is apparent from the first trimester of pregnancy and is manifested in decreased levels of maternal plasma L-arginine and L-homoarginine.
What is known about topic
Nitric oxide (NO), along with its substrates and inhibitors, is thought to have an important role in the pathophysiology of preeclampsia (PE). Several studies have reported that in PE the maternal plasma concentration of ADMA is increased, whereas reported levels of L-arginine before and during PE are contradictory. Few first trimester data have been reported. L-homoarginine levels are increased in normal pregnancy but levels in PE are unknown.
What this study adds
In pregnancies, which subsequently develop early PE the maternal plasma concentrations of L-arginine and Lhomoarginine at 11 --13 weeks' gestation are decreased whereas the concentration of ADMA is not significantly altered.
In women who develop late PE there are no significant differences from normotensive controls in plasma L-arginine, L-homoarginine or ADMA at 11 --13 weeks' gestation. Our findings suggest that development of early PE, but not late PE, is associated with altered NO metabolism and/or synthesis which is apparent from the first trimester of pregnancy.
